Aethlon receives ethics committee approval for hemopurifier® cancer trial in india

Aethlon medical granted full ethics approval from the medanta institutional ethics committee for a safety, feasibility, and dose finding study of its hemopurifier® in cancer patients with solid tumors not responding to anti-pd-1 antibodies san diego , sept. 19, 2024 /prnewswire/ -- aethlon medical, inc. (nasdaq: aemd), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that, on september 9, 2024, the medanta institutional ethics committee (miec) granted full ethics approval for aethlon's safety, feasibility and dose-finding clinical trial of the hemopurifier® in cancer patients with solid tumors who have stable or progressive disease during anti-pd-1 monotherapy treatment, such as keytruda® (pembrolizumab) or opdivo® (nivolumab) (aemd-2022-06 hemopurifier study).
AEMD Ratings Summary
AEMD Quant Ranking